The ACE Gene I/D Polymorphism Is Not Associated With the Blood Pressure and Cardiovascular Benefits of ACE Inhibition
Why the study?
Does the ACE gene I/D polymorphism predict the blood pressure and cardiovascular benefits of perindopril in patients with previous cerebrovascular disease?
Population
5,688 hypertensive and nonhypertensive patients with a history of cerebrovascular disease who participated…
Comparison
Perindopril-based blood pressure-lowering regimen vs Placebo
Design
Cohort
Follow-up
long-term
Authors
Discussion
Loading...
Member takes
Implication
ACE genotyping should not guide perindopril selection post-stroke; leaves open whether other variants influence ACE-inhibitor response.
Structured PICO
Does the ACE gene I/D polymorphism predict the blood pressure and cardiovascular benefits of perindopril in patients with previous cerebrovascular disease?
P
Population
5,688 hypertensive and nonhypertensive patients with a history of cerebrovascular disease (previous stroke or transient ischemic attack) who participated in the PROGRESS trial
I
Intervention
Perindopril-based blood pressure-lowering regimen
C
Comparator
Placebo
O
Outcome
Macrovascular events, dementia, and cognitive declinehard clinical
The ACE gene I/D polymorphism does not predict cardiovascular risk or the therapeutic benefit of perindopril in patients with a history of cerebrovascular disease.
Cite This Study
Harrap et al. (2003) studied this question.